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Abstract
In rectal cancer treatment, both the local primary and the regional and systemic tumour cell deposits must be taken care of in
order to improve survival. The three main treatments, surgery, radiotherapy, and chemotherapy, each with their own
advantages and limitations, must then be combined to improve results. Several large randomized trials have shown that
combinations of the modalities have markedly reduced the loco-regional recurrences, but have not yet had any major inﬂuence
on overall survival. The best integration of the weakest modality, to date the drugs (conventional cytotoxics and biologicals), is
not known. A new generation of trials exploring the best sequence of treatments is required. Furthermore, treatment of rectal
cancer is administered to populations of individuals, based upon clinical factors and imaging, and can presently not be further
individualized. There is an urgent need to develop response predictors.
Key words: Chemoradiotherapy, chemotherapy, local control, multidisciplinary, organ preservation, radiotherapy, randomized
trials, rectal cancer
Introduction
Colorectal cancer is the third most common cancer
worldwide and the second or third most common
cause of cancer death. One-third of the cancers arise
in the rectum, the rest in the colon, and virtually
all cases are adenocarcinomas. Survival has tradi-
tionally been less favourable in rectal than in
colon cancer, but this has recently changed. The
most likely reasons for the presently slightly better
5-year survival rate in rectal cancer (1–3) are the
efforts to decrease rectal cancer local recurrence
rates by better staging, improved surgery, and incor-
poration of radiotherapy. The local recurrence rates
have also substantially decreased from 30%–40% a
few decades ago down to 10%–15% or even lower
in recent studies, and this has had an impact on
survival in certain Western populations. Survival has
also improved with time for patients treated for
colon cancer, but not to the same extent as for rectal
cancer (4).
This review about progress in the care of patients
with rectal adenocarcinoma is based upon a system-
atic approach to the scientiﬁc literature but gives in
addition some personal comments on the develop-
ment during the past 30 years.
Diagnosis and staging
Appropriate diagnosis and staging are fundamental
as regards choice of therapy. Diagnosis is based on
digital rectal examination including rigid sigmoidos-
copy with biopsy for histopathological examination.
The purpose of the biopsy has so far been to obtain
a cancer diagnosis prior to treatment (5). The mor-
phological picture, with the possible exception of
poor differentiation, and other cellular or molecular
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on treatment decisions. Rectal signet-ring cell carci-
nomas are considered to have a particularly poor
prognosis but may respond well to conventional
preoperative therapy (6). Reproducible characteristics
with prognostic and/or predictive properties canhope-
fully soon be identiﬁed. At present, the amount of
cancer cells in the biopsy should at least be sufﬁcient
for an analysis of the KRAS mutational status, since
treatment with an epithelial growth factor receptor
(EGFR) inhibitor could be an option in the future (7).
Tumours with distal extension to 15 cm or less
(as measured by rigid sigmoidoscopy) from the anal
margin are classiﬁed as rectal, more proximal tumours
as colonic. Whether this 15 cm limit is the best one
for choosing a ‘rectal cancer strategy’ or a ‘colon
cancer strategy’ can be discussed. Others prefer to
separate colon and rectal cancers at the peritoneal
reﬂection, or about 9–12 cm from the anal verge.
The localization of the tumour in relation to other
organs and structures and, thus, the distance from the
anal verge is important for outcome and treatment.
From a practical point of view, cancers between
10 and 15 cm are best discussed as rectal cancers
since radiotherapy (RT) is an important component
of therapy, even if less frequently than for lower rectal
cancers (0–10 cm) (8).
Endoscopicultrasonographyfortheearliesttumours
(cT1-2)orrectalMRIforalltumoursisrecommended
in order to select preoperative treatment and extent of
surgery (9,10). The TNM staging system should be
used. There is major controversy about which version
to use. At present, version 5 from 1997 is preferred
by some to the TNM versions 6 (2002) and 7 (2010),
since the latter two show marked interobserver varia-
tionsindeﬁningstageIIandstageIII(11).Atthesame
time, there is a need for further subclassiﬁcation,
particularly of clinical stage T3 (cT3) in order to
individualize therapy, as indicated in Table I.
The importance of local control and overall
strategy in rectal cancer care
Radical removal of the primary rectal cancer and no
local recurrence are prerequisites for cure, although
occasional local recurrences can be salvaged by sec-
ondary surgery and (chemo)radiotherapy ((C)RT).
Avoidance of persistent or recurrent tumour in the
pelvis is important, even if cure cannot be achieved,
since uncontrolled pelvic growth is usually associated
with severe, disabling symptoms. Even if overall sur-
vival is not improved, improved local control is a
legitimate outcome of different interventions in rectal
cancer.
An important aim in rectal cancer is, thus, to treat
so that the risk of residual disease in the pelvis is very
low or preferably less than about 5% in the population
in which curative treatment is intended. This should
be possible in all but the few (£10%) cases who
Table I. TNM classiﬁcation (version 5, 1997) with subclassiﬁcations.
TNM Stage Extension to
Tis N0 M0 0 Carcinoma in situ: intraepithelial or invasion of lamina propria
T1 N0 M0 I Submucosa
T2 N0 M0 I Muscularis propria
T3 N0 M0 IIA Subserosa/perirectal tissue
Substaging
a T3a Less than 1 mm
T3b 1–5m m
T3c 5–15 mm
T3d 15 + mm
T4 N0 M0 IIB (b) Perforation into visceral peritoneum; or (a) invasion to other organs
b
T1–2 N1 M0 IIIA 1–3 regional nodes involved
T3–4 N1 M0 IIIB 1–3 regional nodes involved
c
T1–4 N2 M0 IIIC 4 or more regional nodes involved
T1–4N 1 –2 M1 IV Distant metastases
aThis subclassiﬁcation based upon an evaluation using MRI prior to treatment decision is clinically valuable, and used when describing the
treatment strategy for primary rectal cancer. It can be used also in the histopathological classiﬁcation but is not yet validated and therefore not
incorporated in any of the TNM versions 5–7.
bThis is the subclassiﬁcation in TNM 5. It has been reversed in TNM 6 and 7.
cLymph node classiﬁcation is modiﬁed in TNM 7. Tumour cell deposits without a visible lymph node structure are also considered. It is
recommended to investigate at least 12 nodes for proper staging.
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readily resectable organ (about half of those with
cT4). At the same time, however, as little acute
and late morbidity as possible should be aimed at.
Surgery, particularly if extensive, may give substantial
morbidity, and additional treatments, whether given
pre- or postoperatively, increase morbidity. Thus,
additional treatments should be chosen with care.
From a practical point of view, rectal cancers can be
divided into four groups: very early (some cT1), early
(cT1-2, some cT3), intermediate (most cT3, some
cT4), and locally advanced (some cT3, most cT4).
Factors other than clinical T-stage are also relevant,
such as tumour height, closeness to the mesorectal
fascia (mrf), potentially the circumferential margin
(crm) (preoperatively, the term mrf is better than
crm, since the crm cannot be deﬁned until after
surgery (12)), nodal (cN)-stage, and vascular and
nerve invasion. It is at present not possible to provide
a precise description of which T and N substages
belong to these groups. The terms ‘favourable or early
or good’, ‘intermediate or bad’, and ‘locally advanced
or ugly’ can be used for categorizing the rectal cancers
into these clinical subgroups. The subdivision pres-
ently used in Uppsala and Stockholm, Sweden is
shown in Figure 1.
In clinical practice and in many recent studies, the
term ‘locally advanced’ has been commonly used for
the ‘intermediate/bad’ group but is best reserved for
the truly ‘locally advanced/ugly’ tumours (8,13,14).
The variability in what is called locally advanced
(there is a clear tendency in medicine to use terms
that indicate advanced disease even if this is not really
present) has been extensive, but there is consensus
about the need to subgroup along these lines. Sub-
grouping is an important step towards individualized
medicine. Great discrepancies do, however, exist as
regards which treatment is selected for these sub-
groups between different centres in one country
and for different countries.
There is a clear difference in how the regional, sub-
clinical tumour deposits frequently seen in advanced
tumours below the peritoneal reﬂection are managed
in Asia and the rest of the world. Should those areas
be cleared surgically or by radiation? Surgical removal
of the lateral nodes on one or both sides has been the
preferred option in Asia, whereas the rest of the
world has explored the value of radiation, in addition
to surgery for the primary, to kill tumour deposits.
Since radiation does not selectively irradiate the
lateral nodes, but also includes the primary tumour
and the mesorectal nodes, the need for a meticulous
surgical dissection technique has not developed as
rapidly in the rest of the world as in Asia. Both
extensive surgery and additional radiotherapy increase
morbidity. The questions are twofold: 1) which of
the two alternatives is most efﬁcient in eradicating
all tumour cells, i.e. preventing a local failure, and 2)
which alternative results in the least morbidity? There
are no randomized studies that compare the two
strategies. Comparisons between trials reveal that
the results are equally good at specialized centres,
Favourable ‘good’ group
mid/upper rectum
T1–3b
Low rectum T1–2, T3a
N0
mrf clear
Intermediate ‘bad’ group
mid/upper rectum
T3c/d
low rectum also includes T3b
T4 with peritoneal or vaginal involvement only
N1/N2
Advanced ‘ugly’ group
5 y LFR2) <10% 
mrf clear
5 y LFR2) 10%–20%
T3 mrf positive
T4 with overgrowth to prostate, seminal 
vesicles, base of urinary bladder,
pelvic side walls or floor, sacrum
positive lateral lymph nodes
5 y LFR2) 20%–100%
Primary surgery (TME)3) Preop 5 x 5 Gy with immediate surgery Preop CRT or 5 x 5 Gy with delayed surgery4)
Figure 1. Subgrouping of localized rectal cancer assessed by MRI
1) and recommended primary treatment.
1)The algorithm does not primarily
address the risk of systemic disease, although this risk also increases with the presence of many of ‘the risk factors’, however, not necessarily
parallel to the local failure rate (LFR). The algorithm is also ‘too simpliﬁed’ in that also other factors like size of the mesorectum, anterior or
posterior location, extramural vascular invasion (EMVI+) are relevant. The recommendations are the ones in use at most centres in Sweden in
2011.
2)Calculated inthe groupofpatients plannedforsurgery,i.e.irrespective ofthe surgicaloutcome.The ﬁgures arevalidif the surgeonis an
experienced rectal cancer surgeon and no pretreatment is given.
3)A local procedure is possible in a few patients (chieﬂy pT1, sm1 (+2), N0).
This group is in the text referred to as ‘very favourable’.
4)CRT means chemoradiotherapy to 50.4 Gy in 1.8 Gy fractions with 5-ﬂuorouracil
(capecitabine); 5  5 Gy with delayed surgery is used in patients not ﬁt for CRT.
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Theoretically and in clinical practice, it is more
efﬁcient to ‘hunt’ subclinical cancer deposits using
radiation than using surgery unless you can dissect
in a surgical plane. The resultant morbidity is very
different, although the impact of this on well-being
differs between cultures.
In the Western world where the beneﬁts of radia-
tion therapy to surgery were studied (a preoperative
approach was mainly explored in Europe, whereas a
postoperative approach was explored in the USA) few
small studies indicated that postoperative CRT was
better than postoperative RT in preventing local
recurrence and that treatment was more effective
than no additional treatment. Based upon this evi-
dence, a NIH Consensus Conference and a subse-
quent NCI report stated that postoperative CRT
should be standard treatment in rectal cancer stages
II and III (15,16). A small Norwegian trial also found
that postoperative CRT was better than no additional
treatment, but the evidence for a clear beneﬁt from
postoperative CRT considering its toxicity over RT
alone has been questioned (17).
In Europe, in contrast, several randomized trials
compared surgery alone versus preoperative RT and
surgery. These studies showed, particularly if short-
course RT (the Swedish 5  5 Gy schedule) with
immediate surgery was used (18), a relative reduction
in local failure rates of 50%–60% in all trials including
many hundreds to over a thousand patients. Based
upon these experiences, preoperative RT was recom-
mended early on as routine therapy in many coun-
tries, but not until quite recently in most countries.
Pre- or postoperative, short- or long-course,
with or without chemotherapy?
For about two decades, four questions have domi-
nated the arena: 1) Should the RT be given before or
after surgery? 2) Should it be long-course or short-
course? 3) Should the long-course RT be given alone
or with chemotherapy? (In Europe researchers were
not convinced of the advantages of adding concom-
itant chemotherapy, as stated in the USdocuments).
In addition: 4) As sphincter-saving surgery (SSS) was
considered important, could it be increased after pre-
operative (C)RT? (This was debated extensively and
was subject to several trials).
Pre- or postoperative?
A randomized trial showed at an early date that
preoperative short-course RT was more effective
than postoperative long-course RT. In that trial
(19,20), a brief preoperative schedule was superior
to an optimized postoperative high-dose schedule.
Subsequently, several trials comparing preoperative
CRT with postoperative CRT were initiated. Only
one of them completed patient accrual (21). It showed
(again) that a preoperative approach was more efﬁ-
cient and less toxic. Superiority of preoperative short-
course RT over postoperative CRT was also shown
in the MRC-CR07 trial (22). Most of the world has
now accepted that additional (C)RT in rectal cancer
should be given before rather than after surgery. An
analysis of data from all randomized studies also
indicated that preoperative RT is more dose-efﬁcient
than postoperative RT (23).
Short- or long-course?
The question of short-course (5  5 Gy) versus
long-course conventional RT (1.8–2.0 Gy  25–28)
has not yet been settled. A randomized study, the
Stockholm III trial, is on-going (700/840 patients
have been randomized). In two trials including 316
and 326 patients, respectively, there was no difference
in local recurrence rates, disease-free (DFS), and
overall survival (OS) between the groups randomized
to short-course RT alone or long-course CRT (24,25).
The short-course schedule has gained much pop-
ularity in Northern European countries where health
care systems are rarely dependent upon private initia-
tives, whereas the long-course schedule is preferred
in countries where physician and hospital budgets
are inﬂuenced by the number of treatments given.
Reimbursementhas thusinﬂuenced routines, although
this has never been ofﬁcially admitted. Many con-
cerns have been expressed about the long-term
consequences of hypofractionated RT. There is con-
siderable evidence that the short-course schedule
results in long-term morbidity, and the scale of that
morbidity is now well known (26). The long-term
morbidity of CRT whether given preoperatively or
postoperatively has not been studied systematically,
with the result that the extent of late morbidity is not
known. Both options, short-course 5  5 Gy and
long-course CRT are considered valid in the inter-
mediate group of rectal cancers (8).
Without or with chemotherapy?
The third question, whether or not the long-course
RT should be combined with chemotherapy, was
answered after the completion of three randomized
trials: two in the intermediate group (27,28) and one
in the locally advanced, ugly group (29). Local control
was better in the combined treatment arm in all three
228 B. Glimeliusstudies, whereas a signiﬁcant survival gain was only
seen in the trial including locally advanced cancers
(13,29). Whenever a patient with a locally advanced
rectal cancer receives preoperative treatment, CRT
should be used unless the patient cannot tolerate this
treatment. It should, however, be recognized that the
gains from the chemotherapy addition are limited and
come with a rather high price.
Sphincter preservation, organ preservation
Trials, again chieﬂy run in Europe, have explored
whether long-course (C)RT with a delay before sur-
gery could increase SSS rates, whereas others took it
for granted that this was the case. Trials have later
shown that this effect did not occur to any meaningful
extent (30). Hopes about improved chances of SSS
inﬂuenced routines in many countries, particularly in
Southern Europe, Germany, and the USA. At pres-
ent, hopes about organ preservation (see below) inﬂu-
ence treatment decisions in different ways in different
parts of the world.
Need for quality assurance and control
Treatment of rectal cancer is demanding and requires
great skill in the entire multidisciplinary team (MDT).
Good surgery and good pathology, as well as good
radiation techniques and administered chemotherapy,
together with long-term complete follow-up, also
including functional aspects, are important for quality
control. Many countries have recently launched
quality assurance (QA) and quality control (QC)
programmes in rectal cancer surgery. They have
been beneﬁcial for outcome (31,32). Although com-
ponents other than surgery have been dealt with
within the clinical guidelines/care programmes, these,
like RT and CRT, must also be fully integrated in the
QA and QC programmes.
Risk-adapted treatment
Very favourable rectal cancer
In the earliest, most favourable cases, chieﬂy the
malignant polyps (Haggitt 1–3, T1 sm1 (-2?) N0),
a local procedure, e.g. using the transanal endoscopic
microsurgery (TEM) technique, is appropriate
(33,34). The resection should be radical (R0) without
signs of vessel invasion or poor differentiation. If this
is not the case or if the tumour inﬁltrates deeper into
the submucosa (Haggitt 4, T1 sm(2?-)3) or a
T2 tumour, the risk of recurrence because of
remaining tumour cells or because of lymph node
metastases is too high ( 10%), and the patient should
have postoperative CRT or, more safely, be recom-
mended major surgery (total mesorectal excision). If
the cancer diagnosis is veriﬁed in a biopsy, presurgical
CRT is preferred if the intent is to perform a local
procedure (33). As an alternative to local surgery,
alone or with (preoperative) CRT, local RT (brachy-
therapy or contact therapy (Papillon technique)) can
be used in the most favourable cases. Experience of
these treatments is limited outside specialized centres
(35), and more prospective studies are required
before these techniques can become a part of clinical
routines.
Favourable, ‘good’ rectal cancers
In the early, favourable cases (cT1-2, some early cT3,
N0 (cT3a(-b) and clear mrf (mrf-) according to
MRI), ‘good’ group) above the levators, surgery
alone, meaning a sharp radical dissection using the
total mesorectal excision (TME) technique, is appro-
priate, since the risk of local failure is low (8).
Although large randomized trials, where short-course
RT has been given, have indicated that this treatment
reduces local recurrence rates even further (18,22,36),
surgery alone is recommended since the addition of
preoperative RT results in overtreatment of too many
individuals (8). The balance between the reduction
in local recurrence rates and long-term morbidity is
intricate.
Intermediate, ‘bad’ rectal cancers
In the intermediate or ‘bad’ group (most cT3 (cT3(b)
c + without threatened or involved mrf (mrf-) accord-
ing to MRI), some cT4 (e.g. vaginal or peritoneal
involvement only), N+), preoperative RT is recom-
mended followed by TME, since this reduces local
recurrence rates. Even in the absence of signs of
extramural growth on ultrasound or MRI (cT2) in
very low tumours (0–5 cm), preoperative RT may be
indicated because the distance to the mrf is very small.
Treatment with 25 Gy delivered during one week
followed by immediate surgery (<10 days from the
ﬁrst radiation fraction) is convenient, simple, and
low-toxicity (18,22,36,37). Several trials have shown
that the risk of local failure in the randomized pop-
ulation selected for later resection, i.e. the intention-
to-treat population, has been reduced by 50%–70%
versus surgery alone. More demanding, and not
proven more effective, alternatives are 46–50.4 Gy,
1.8–2 Gy/fraction with 5-FU (bolus, continuous
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was added to the preoperative radiation primarily
based upon extrapolations from the postoperative
RT trials in rectal cancer. Two large European trials
(27,28) recently showed that the addition of 5-FU
improves local control with reduced local failure rates
after 5 years. These were 16%–17% in the preoper-
ative RT arms alone and 8%–10% in the CRT arms.
In the EORTC trial, the same reduction was seen
irrespective of whether the chemotherapy was admin-
istered concomitantly or only postoperatively. Two
trials have randomized between preoperative 5  5G y
and preoperative CRT (5-FU + 50.4 Gy) without
detecting any statistically signiﬁcant difference in
local recurrence rates, DFS, and OS (24,25). In
the MRC-CR07 trial including 1350 patients, preop-
erative 5  5 Gy was randomly compared with post-
operative CRT if the crm was positive. Local
recurrence rates favoured the preoperative arm (5%
versus 17%, P < 0.001) (22). DFS was also superior in
the preoperative arm (hazard ratio (HR) 0.76,
P = 0.01), whereas OS did not differ signiﬁcantly
(HR 0.91, P = 0.04).
Locally advanced, ‘ugly’ rectal cancers
Inthemostlocallyadvanced,frequentlynon-resectable
cases (cT3 mrf+, cT4 with overgrowth to other organs
(cT4)), preoperative CRT, 50.4 Gy, 1.8 Gy/fraction
with concomitant 5-FU-based therapy should be used
(8,13,29), followed by radical surgery 6–8 weeks later.
In a Nordic randomized trial (cT4NXM0), local con-
trolwassigniﬁcantlybetterafter5yearsintheCRTarm
(5-FU + 50 Gy) than in the RT only arm (82% versus
67%, P =0.03). Also DFS and cancer-speciﬁc survival
weresigniﬁcantlybetterinthecombinedmodalityarm,
whereas OS did not signiﬁcantly differ (66% versus
53%, P = 0.09) (29).
In very old patients (above 80–85 years) and in
patients not ﬁt for CRT, 5  5 Gy with a delay of
approximately 8 weeks before surgery can be an
alternative option, presently under clinical validation
after a favourable report ﬁrst from Uppsala, Sweden
and subsequently Leeds, UK (38,39).
Which chemotherapy schedule? Targeted drugs?
Standard preoperative CRT means a dose of
46–50.4 Gy together with 5-FU given either as
bolus injections with leucovorin 6–10 times during
the radiation (as in the trials proving that CRT pro-
vides better local control than the same RT alone)
(13,27-29), prolonged continuous infusion (in all
probability better than bolus), or oral capecitabine
or UFT. Combinations of 5-FU or other antifolates
with other cytostatics, like oxaliplatin or irinotecan,
or targeted biological drugs have been extensively
explored in phase I–II trials, which have claimed
more favourable results (more downsizing, higher
pathological complete response (pCR) rates), but
also more acute toxicity. Several comparative ran-
domized trials using oxaliplatin are on-going. The
initial results of these are not favourable (ACCORD
12/Prodige-2 (40) and SA-01 (41)), and these com-
binations are still experimental. Nor are the initial
results of adding targeted drugs like cetuximab, pani-
tumumab, or bevacizumab favourable (42-46). When
cetuximab was added to neoadjuvant oxaliplatin-
capecitabine and preoperative CRT in the randomi-
zed phase II EXPERT-C trial, more radiological
responses were seen in the cetuximab arm (89%
versus 72%, P = 0.003) than in the KRAS wild-
type population (n = 90) (47). Overall survival was
also improved (96% versus 81% at 3 years, P = 0.04).
Organ preservation?
Apart from the earliest tumours that can be treated
with a local procedure or local RT, as described
above, it has become increasingly popular to deliver
CRT ﬁrst, wait, and restage the tumour with multiple
biopsies/excision biopsy of the previous tumour area
(48,49). If no viable tumour cells are then found, no
further therapy is delivered (organ preservation), and
the patient is monitored closely for at least 5years.It is
then assumed that potential lymph node metastases
have been eradicated in parallel with the excellent
response of the primary tumour. Although this may
undoubtedly occur in some patients, this strategy has
not been subject to properly controlled prospective
studies. It is likely that this excellent response will not
be frequently seen in intermediate and locally
advanced cases (50), but rather only in early cases.
The advantages (no major surgery and no rectal
excision if the tumour is very low) are apparent for
certain individuals who run a very high risk from
surgery or who cannot accept a stoma. However,
the disadvantages for many others are seldom dis-
cussed. In most patients with an early ‘good’ rectal
cancer, a low anterior resection alone is the preferred
therapeutic option. Cure rates are high, and morbidity
is only a result of surgery. If these patients are instead
treated with the aim of organ preservation, all will
receive CRT with its acute morbidity. Those clinically
responding very well could then be cared for with a
wait-and-see policy. These are the patients who could
potentially beneﬁt from this approach, although they
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be seen after CRT. This is, as indicated above, not
well studied. If the tumour is located in the lower
rectum, at least part of the sphincters must be inclu-
ded in the irradiated volume, and poor anal function
can be a result. For those not responding well or those
recurring during follow-up, major surgery is required.
These patients will thus suffer the morbidity inherent
to both CRT and surgery. No study has so far had a
prospective design so that it is possible to obtain an
idea of the proportion of patients who do not require
major surgery. With the CRT schedules available
today, it is this author’s opinion that the group of
patients having a true advantage is much smaller than
the group of patients who suffers extra morbidity.
Evaluation of response after preoperative (chemo)
radiotherapy
Since the response to preoperative therapy (5  5G y
with a delay or prolonged CRT to 46–50.4 Gy) inﬂu-
ences prognosis (51,52) and thus subsequent therapy,
both the extent of surgery and postoperative chemo-
therapy, attempts clinically and pathologically to
restage the tumours have been made. There is
increasing experience in evaluating tumour response
by repeat MRI or PET-CT. Using MRI, a decrease in
size can be seen, as well as an increase in ﬁbrosis, and
mucous degeneration, indicating response (53).
Using FDG-PET, a decrease in uptake can be seen
(54-57). At present, the knowledge about the rele-
vance of these changes is too uncertain to modify the
extent of surgery. Other attempts to evaluate response
after CRT have also been made (58).
Several systems for pathological tumour regression
grading have been used (e.g. by Mandard 1994;
Dworak 1997; Wheeler 2002; Roedel modiﬁcation of
Dworak 2005). The best approach as regards repro-
ducibility,prognosticinformation,etc.isnotyetknown.
The tumours should at least be graded into three
groups: complete response (pCR), some (potentially
in the future, good, moderate, and poor) response, and
noresponse.TheproportionofpCRs,meaningabsence
of tumour cells after a given treatment for a certain
substage, is inﬂuenced by intensity of dissection.
A standardization of the dissection is required if pCR
rates are to be used as a valid end-point (59).
Postoperative adjuvant therapy
Postoperative CRT (e.g. about 50 Gy, 1.8–2.0 Gy/
fraction)withconcomitant5-FU-basedchemotherapy
is,assaidabove,nolongerrecommendedbutcouldbe
used in patients with positive crm, perforation in the
tumour area, or in other cases with high risk of local
recurrence if preoperative RT has not been given. The
strategyofgivingpostoperativeCRTtocrm+tumours
was, however, inferior to giving preoperative 5  5G y
to all, according to the MRC-CR07 trial (22).
Similar to the situation in colon cancer stage III
(and ‘high-risk’ stage II), adjuvant chemotherapy can
be provided, even if the scientiﬁc support for sufﬁcient
effect is less than in colon cancer (60,61). In the early
chieﬂy American trials, both chemotherapy and CRT
were predominantly given, and thus it was difﬁcult to
ascertain which component was responsible for the
survival gain (15,16). It is possible that the efﬁcacy of
adjuvant chemotherapy is less if the tumour has not
responded to the CRT, but this is based only upon a
retrospective analysis of one trial (62).
Radiation therapy volumes and doses
Whenever RT is indicated to lower the risk of local
failure in the ‘intermediate/bad’ group or to cause
downsizing to allow radical surgery in ‘locally
advanced/ugly’ tumours, the primary tumour with
the mesorectum and lymph nodes outside the meso-
rectum, at risk to contain tumour cells, should be
irradiated more than exceptionally (63,64). In the
‘early/good’ group before or after a local procedure,
only mesorectal nodes are considered at sufﬁcient risk
to be involved. The appropriate dose to subclinical
disease is not precisely known, but should with 5-FU
chemotherapy be at least 46 Gy in 1.8–2 Gy fractions.
The relative reduction in local failure rates is then in
the order of 50%–60%, and subsequently there is
room for improvement. A boost of about 4–6G yi n
2–4 fractions to the primary tumour is often given,
limiting the radiation dose to the entire volume when
long-course CRT is given (65).
The entire mesorectum is at great risk of having
tumour deposits, often in the mesorectal lymph
nodes, in all tumours except the very earliest
(T1 sm1 (-2?)) and should be included in the clinical
target volume (CTV). An exception is the high
tumours where it is sufﬁcient to include the 4–5c m
distal to the tumour. Besides the mesorectal nodes,
the presacral nodes along aa. rectales superiores up
to the level of S1-2 (if presacral nodes are radiologi-
cally involved), the upper border of CTV should be
even higher. Local recurrences above S1-2 are rarely
seen (66-68). The lateral nodes along aa. rectales
inferiores and aa. obturatorii and the internal iliac
nodes up to the bifurcation from aa. iliacae commu-
nes should be included in tumours below the perito-
neal reﬂection, i.e. in tumours up to about 9–12 cm
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involvement in the Western world is not properly
known, but studies from Asia show that these lymph
nodes are rarely involved in low–mid rectal pT1-2-
tumours and in high tumours irrespective of T-
stage (70,71). External iliac nodes should only be
included if an anterior organ, like the urinary bladder,
prostate, or female sexual organs, is involved to such
an extent that there is a risk of involvement of these
lymph node stations. The medial inguinal nodes need
only to be prophylactically included when the tumour
grows below the dentate line (72). When lymph nodes
are involved by metastatic disease so that this can be
seen on imaging, there is always a risk of aberrant
spread, and the CTV can be enlarged to include other
nodal stations than those described above.
Fossae ischiorectales should only be included when
the levator muscles and the internal and external
sphincters are involved since the fascia inside the
levators is considered to be a strong barrier to tum-
our cell penetration (73). Other opinions have been
expressed (63).
Late toxicity from rectal cancer radiotherapy
It is extremely important to know the extent of late
toxicity after rectal cancer RT if this is delivered pre- or
postoperatively to diminish the risk of local recurrence.
The prevention of a local failure must be weighed
against the morbidity from (C)RT that all treated
patients can develop. Studies have tried to estimate
what minimal absolute gain should be present for
patients to prefer RT. These studies are very difﬁcult
to interpret, although many patients accept an absolute
3%differencefortheknownmorbidityrisksofRT(74).
From the Swedish and Dutch randomized trials,
we have good evidence of the morbidity after 5  5
Gy RT (summarized in (26)). It is beyond the
scope of this review to detail this toxicity, but
increased risks of poor anal and sexual function,
small-bowel toxicity with obstruction, and secondary
malignancies have been reported. After having
worked with rectal cancer patients for over 30 years,
and thus meeting many patients with a local recur-
rence during the ﬁrst part of the period, and being
actively involved in the research to estimate the
extent of late toxicity up to 20 years after the RT,
it is my opinion that an absolute risk reduction of
approximately 5% motivates the recommendation to
irradiate.Furthermore, and very importantly, the RT
we give today, and the RT we can routinely give in
only a few years, will mean less late toxicity than that
seen in the follow-up studies of the RT delivered
during the 1980s–1990s (64,75,76).
A very important question as yet unresolved is the
late toxicity from 5  5 Gy compared with the toxicity
seen after 46–50 Gy in 25–28 fractions, usually
administered with 5-FU. We know the long-term
morbidity from 5  5 Gy up to at least 10 years
follow-up (with yesterday’s techniques) from studies
including thousands of patients. We do not have
this knowledge from CRT. The Polish (24) and the
MRC-CR07 trials (22) have reported late toxicity
after 4 years of follow-up, without being able to
detect any differences between 5  5 Gy and CRT
to 46–50 Gy. The short-course schedule uses a high
fraction size of 5 Gy, compared with 1.8–2.0 Gy,
whereas the total dose is less (25 Gy compared to
46–50 Gy). Both the fraction size and the total dose
are relevant. The relationship between total dose,
fraction size, and late toxicity is, however, complex.
Another yet unresolved question is whether the
addition of 5-FU or in the future other drugs increases
late toxicity. In one of the two larger randomized trials
in the intermediate risk group (27,28), the addition of
5-FU affected global quality of life (QoL), social
functioning, and diarrhoea negatively. Almost 60%
of the patients suffered faecal incontinence, impairing
their social life (77). In the trial in locally advanced/
ugly cancers, more patients had a stoma or a poor anal
function in the CRT group than in the RT group
(89% versus 70%, P = 0.046) (78), but there were no
differences in QoL after 4–8 years (79). Whether this
means that the chemotherapy addition results in more
late toxicity or if this difference reﬂects survival of
patients with more advanced tumours in the CRT
group cannot be deduced.
Conclusions and future development
During the past three decades, I have witnessed the
disappearance of a severely disabling condition for
many rectal cancer patients, namely a local failure
with uncontrolled growth of the cancer in the peri-
neum and pelvis. The surgeon, Åke Rimsten, who in
1978 together with the oncologist Sten Graffman
started preoperative radiotherapy in rectal cancer
patients in Uppsala, had found that a local rectal
cancer failure was the individually most common
reason for a patient to occupy a surgical bed in the
health care region (unpublished information, see
(80)). Together with the surgeon Lars Påhlman,
who joined the team in late 1979 as a PhD student,
it has been possible during the three decades to
improve many details in the total care of these patients.
Multiple trials have conﬁrmed the superiority of what
we presently consider as recommended care and
treatment (Figure 1). A multidisciplinary approach
232 B. Glimeliushas been "a must" in this development, at present
formalized as weekly multidisciplinary team (MDT)
meetings, during which all patients are discussed,
before the ﬁrst treatment decision, postoperatively,
and at critical time points during the course of the
disease.
Practically all details in the care of the patients have
been subjected to prospective, frequently randomized
trials. With time, you tend to forget selectively,
thereby modifying history, but the only research ethics
committee approved trial that completely failed was
one in patients with a local failure; the patients simply
disappeared around 1983–1984. For a variety of rea-
sons, many of the necessary quality improvements,
even if proven superior in large randomized phase III
trials, have not been introduced at other hospitals
until 10–20 years later. It should also be recognized
that many uncertainties about what is the best treat-
ment still exist. Furthermore, alternative approaches
to attaining low local failure rates, improved survival,
together with as few negative consequences from the
disease and its treatment as possible, also exist.
The trials have now repeatedly shown that RT,
whether alone or with chemotherapy, should be given
before surgery to have the best efﬁcacy and least
toxicity. This was shown as early as in 1985 but is
not until now unanimously agreed upon. It is also my
belief that the systemic treatment, being the weakest
part of the therapy, should be given before and not
after surgery in order to have greatest efﬁcacy. Pro-
gression of the local primary tumour should then not
occur during the systemic treatment, presently requir-
ing a duration of 5–6 months. The discovery that the
short-course schedule resulted in substantial down-
staging, was tolerable, and permitted full chemother-
apy starting soon after the RT (38), together with the
same experiences by other groups, has led to the next
generation of studies, such as the ‘Nordic Dream’ or
the multicentre ‘RAPIDO’ trial. In the trial where
patient inclusion started in June 2011, patients with
‘ugly’ rectal cancers are randomized to the present
standard, CRT, surgery and adjuvant chemotherapy
(even if not all consider this standard), and an exper-
imental arm with 5  5 Gy, neoadjuvant chemother-
apy, and surgery at the end.
During the past 30 years, it has also been possible
to witness the enormous expansion in knowledge
in tumour biology. Better understanding of the
molecular mechanisms behind tumour development
and progression has created great expectations of
improved diagnosis, staging, prognostic evaluation,
and selection of the individually best therapy. I have
been part of these efforts, attempting to pick up the
basic ﬁndings and apply or translate them into useful
clinical tools. During the course of these efforts, much
new and valuable information has been created, but
no new clinically valuable markers have been identi-
ﬁed. I am not alone in feeling frustrated when the
number of mm’s from the most peripheral part of the
rectal tumour to the mrf (or crm postoperatively) and
the ratio of the number of metastatic lymph nodes to
the number of sampled nodes are the most informa-
tive markers. No predictor of which pre- (or post)
operative treatment to choose is available. The efforts
to translate basic knowledge into clinically useful
information must be intensiﬁed or maybe explored
along other paths. Sampling of representative and
sufﬁcient tumour material not only for diagnosis
but also for research prior to, during, and after therapy
may help. Functional imaging giving information
directly or indirectly on where to sample may also
be helpful. Repeated sampling is ethically controver-
sial but could be motivated if coupled to highly skilled
research groups both in clinical and preclinical areas.
At any rate, we need predictors and must ﬁnd better
ways of identifying them.
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